Rabbit Polyclonal TGFbeta RII antibody (STJ95994)

$99.00$319.00

Reactivity: Human, Mouse, Rat
Applications: WB, IF
Conjugation: Unconjugated
Supplier: St John’s Laboratory Ltd.

Clear
-$50 as credit for submitting review for primary antibody
Shipping notice:
Product will be delivered in 6 to 8 Business Days

Antibody Validation Project, Antibody Trial Sample, Antibody Free Sample for your own antibody validation and submitting antibody reviews, AntibodyPlus

Rabbit Polyclonal TGFbeta RII antibody (STJ95994)

Supplier: St John’s Laboratory Ltd.

Recommended applications: WB, IHC, ELISA

Recommended dilution: WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000;

Recommended protocols: check protocols

Image descriptions:

Click or hover above images to see image description for TGFbeta RII Polyclonal Antibody.

Alternative names:

Check alternative names for the antibody

Expand

TGFBR2 antibody,|AAT3 antibody|FAA3 antibody|LDS1B antibody|LDS2 antibody|LDS2B antibody|MFS2 antibody|RIIC antibody|TAAD2 antibody|TbetaR II antibody|TbetaR-II antibody|TGF beta receptor type 2 antibody|TGF beta receptor type II antibody|TGF beta receptor type IIB antibody|TGF beta type II receptor antibody|TGF-beta receptor type II antibody|TGF-beta receptor type-2 antibody|TGF-beta type II receptor antibody|TGF-beta-R2 antibody|TGFB R2 antibody|TGFbeta – RII antibody|TGFbeta RII antibody|Tgfbr2 antibody|TGFR-2 antibody|TGFR2_HUMAN antibody|Transforming growth factor beta receptor II antibody|Transforming growth factor beta receptor type II antibody|Transforming growth factor beta receptor type IIC antibody|Transforming growth factor, beta receptor II (70/80kDa) antibody|transforming growth factor, beta receptor II alpha antibody|transforming growth factor, beta receptor II beta antibody|transforming growth factor, beta receptor II delta antibody|transforming growth factor, beta receptor II epsilon antibody|transforming growth factor, beta receptor II gamma antibody|Transforming growth factor-beta receptor type II antibody|Anti-TGF beta Receptor II antibody [MM0056-4F14] (ab78419)
SCBT cat No: sc-17005|sc-17006|sc-17007|sc-71945|sc-69930|sc-71944|sc-69931|sc-57416|sc-80924|sc-9678|

Name

TGFbeta RII Polyclonal Antibody

Catalogue No.

STJ95994

Reactivity

Human, Mouse, Rat

Specificity

TGFbeta RII Polyclonal Antibody detects endogenous levels of TGFbeta RII protein.

Immunogen

Synthesized peptide derived from TGFbeta RII at AA range 60-140

Host

Rabbit

Applications

WB, IHC, ELISA

Recommended dilution

WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:20000;

Clonality

Polyclonal

Conjugation

Unconjugated

Isotype

IgG

Molecular weight

65 kDa

Formulation

TGFbeta RII Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration

1 mg/ml

Purification

TGFbeta RII Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Storage

-20 Celsius degree. Avoid repeated freeze/thaw cycles.

Alternative antibody names

TGF-beta receptor type-2 antibody, TGFR-2 antibody, TGF-beta type II receptor antibody, Transforming growth factor-beta receptor type II antibody, TGF-beta receptor type II antibody, TbetaR-II antibody

Database links

Human UniProt/Swiss-Prot:P37173;Mouse UniPort/Swiss-Prot: Q62312;Rat UniProt/Swiss-Port: P38438;Human Entrez Gene: 7048;Mouse Entrez Gene: 21813;Rat Entrez Gene: Rn.9954

Protein names

TGF-beta receptor type-2 , TGFR-2 , TGF-beta type II receptor , Transforming growth factor-beta receptor type II , TGF-beta receptor type II , TbetaR-II

Protein function

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways. / ATP + [receptor-protein] = ADP + [receptor-protein] phosphate. / Mg2+

Involvement in disease

Hereditary non-polyposis colorectal cancer 6 (HNPCC6) [MIM:614331]: An autosomal dominant disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early-onset colorectal carcinoma (CRC) and extra-colonic tumors of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Clinically, HNPCC is often divided into two subgroups. Type I is characterized by hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II is characterized by increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term ‘suspected HNPCC’ or ‘incomplete HNPCC’ can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Esophageal cancer (ESCR) [MIM:133239]: A malignancy of the esophagus. The most common types are esophageal squamous cell carcinoma and adenocarcinoma. Cancer of the esophagus remains a devastating disease because it is usually not detected until it has progressed to an advanced incurable stage. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Loeys-Dietz syndrome 2 (LDS2) [MIM:610168]: An aortic aneurysm syndrome with widespread systemic involvement, characterized by arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Physical findings include prominent joint laxity, easy bruising, wide and atrophic scars, velvety and translucent skin with easily visible veins, spontaneous rupture of the spleen or bowel, and catastrophic complications of pregnancy, including rupture of the gravid uterus and the arteries, either during pregnancy or in the immediate postpartum period. Some patients have craniosynostosis, exotropy, micrognathia and retrognathia, structural brain abnormalities, and intellectual deficit. . Note: The disease is caused by mutations affecting the gene represented in this entry. TGFBR2 mutations Cys-460 and His-460 have been reported to be associated with thoracic aortic aneurysms and dissection (TAAD). This phenotype, also known as thoracic aortic aneurysms type 3 (AAT3), is distinguised from LDS2 by having aneurysms restricted to thoracic aorta. As individuals carrying these mutations also exhibit descending aortic disease and aneurysms of other arteries (PubMed:16027248), they have been considered as LDS2 by the OMIM resource. .

Protein sequence and domain

Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily. / Contains 1 protein kinase domain.

Protein post-translational modifications

Phosphorylated on a Ser/Thr residue in the cytoplasmic domain.

Protein cellular localization

Cell membrane / Single-pass type I membrane protein / Membrane raft

Research area

All research areas>Membrane Receptors>TGF beta RII
(View all antibody categories related to Membrane Receptors)

Note

AntibodyPlus can customize TGFbeta RII Antibody according to your requirement, including bulk product size,etc. Please contact info@antibodyplus.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.

Supplier

St John’s Laboratory Ltd.

Product type

Primary antibody

Reviews


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review

There are no reviews for this product yet.
By submitting a review, get following benefits:

1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!

view database submit reviews
 

Immunofluorescence analysis of Rat kidney tissue

1: TGFbeta RII Polyclonal Antibody(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.
 

Immunofluorescence analysis of Rat kidney tissue

1: TGFbeta RII Polyclonal Antibody(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.
 

Immunofluorescence analysis of Rat spleen tissue

1: TGFbeta RII Polyclonal Antibody(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.
 

Immunofluorescence analysis of Rat spleen tissue

1: TGFbeta RII Polyclonal Antibody(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.
 

Immunofluorescence analysis of Mouse kidney tissue

1: TGFbeta RII Polyclonal Antibody(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.
 

Immunofluorescence analysis of Mouse kidney tissue

1: TGFbeta RII Polyclonal Antibody(red) was diluted at 1:200 (4 degree Celsius,overnight).
2: Cy3 labled Secondary antibody was diluted at 1:300 (room temperature, 50min).
3: Picture B: DAPI(blue) 10min. Picture A:Target. Picture B: DAPI. Picture C: merge of A+B.


Welcome to AntibodyPlus!